This invention provides PAI-1 inhibiting compounds of Formula I: ##STR00001## wherein: R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are each H, alkyl, alkanoyl, halo, OH, aryl optionally substituted with R.sub.8, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, perfluoroalkoxy; R.sub.5 is H, alkyl, perfluoroalkyl, aryl optionally substituted with R.sub.5, alkanoyl, aroyl optionally substituted with R.sub.8; R.sub.6 is H, alkyl, alkylaryl, benzyl optionally substituted with R.sub.8, alkanoyl, aroyl optionally substituted with R.sub.8; R.sub.7 is H, alkyl, alkylaryl, aryl optionally substituted with R.sub.8; n is 0-6; A is COOH, or an acid mimic such as tetraazole, SO.sub.3H, PO.sub.3H.sub.2, tetronic acid, etc.; R.sub.8 is H, alkyl, cycloalkyl, alkanoyl, halo, OH, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, perfluoroalkoxy; or a pharmaceutically acceptable salt thereof; as well as pharmaceutical compositions and methods of treatment using these compounds.